biochemical reactions. 7, 8 Iron is a component of hemoglobin, which is crucial for oxygen transport to tissues. It also plays a role in oxygen storage (myoglobin) and oxidative metabolism (component of oxidative enzymes and respiratory chain proteins) and is involved in the synthesis and breakdown of carbohydrates, lipids, and nucleic acids. [7] [8] [9] [10] It is increasingly recognized that many patients with chronic heart failure (CHF) have associated iron deficiency. These patients experience worse symptoms compared to those who are ironreplete and are at a higher risk of morbidity and mortality. This article discusses the prevalence of iron deficiency in heart failure and its underlying pathophysiology and examines current clinical practice in the management of iron-deficient CHF patients. This article also identifies points of controversy and highlights areas for future research.
| IRON METABOLISM AND ETIOLOGY OF IRON DEFICIENCY IN CHRONIC HEART FAILURE
Although iron plays an important physiological role, an excess leads to significant toxicity and end-organ damage as seen in disease states of iron overload and inherited defects in iron metabolism such as hereditary hemochromatosis. As there is no specific mechanism for iron excretion, iron absorption and subsequent metabolism are tightly regulated. Homeostasis is then maintained by loss of iron through the turnover of skin and gut epithelial cells and bleeding. 11 Iron is primarily absorbed in the duodenum and jejunum via the divalent metal transporter protein on the luminal cell membrane. Ferric iron is reduced to its ferrous form by the enzyme ferric reductase, and cytoplasmic ferrous iron is either packaged as ferritin for intracellular storage or transported across the basolateral membrane into the circulation. This process involves oxidization back to its ferric form by the enzyme hephaestin oxidase and export through ferroportin iron channels allowing absorbed iron to be transported through the circulation bound to transferrin.
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Circulating iron is avidly taken up by hepatocytes, splenic cells, and bone marrow. Iron is incorporated into heme for bone marrow hematopoiesis or packaged as ferritin for iron storage particularly within the liver and spleen. Senescent erythrocytes are broken down by reticuloendothelial macrophages in the liver and spleen releasing further iron for either storage or circulation. 11, 12 Distinguishing between stored and circulating iron is key to characterizing iron deficiency, which can be classified as either absolute or functional. 12, 13 Absolute deficiency represents a depletion of iron stores, while functional deficiency includes:
1. Normal iron stores but impaired mobilization of iron into the circulation thereby restricting iron availability for cell metabolism and erythropoiesis.
2. An insufficient supply of iron to meet the demands of enhanced erythropoiesis brought about by either anemia of another cause or excessive endogenous erythropoietin production.
Although ferritin is the predominant form of intracellular stored iron, a proportion of this enters the circulation. Serum ferritin levels can therefore serve as a surrogate marker of iron stores. Systemic inflammation, however, results in the release of acute-phase reactants, including ferritin, therefore limiting the validity of the relationship between serum ferritin levels and levels of stored iron in many chronic conditions. Perhaps more important is the amount of circulating iron available for cell metabolism. This can be estimated as a percentage of circulating transferrin saturated with iron (T SAT ). 13 Many proinflammatory cytokines have been implicated in the progression of CHF. Of these, the most important ones appear to be tumor necrosis factor-α (TNF-α), interleukin (IL)-1, and IL-6. 14 In mouse models, both TNF-α and IL-1 induce the synthesis of ferritin by macrophages and hepatocytes. 15, 16 Divalent metal transporter 1 (DMT1), a transmembrane iron transport protein, is involved in the uptake of iron by macrophages and is upregulated in the presence of TNF-α, interferon-γ, and lipopolysaccharide. 17, 18 These proinflammatory cytokines also stimulate retention of iron in macrophages by downregulating the expression of ferroportin. 18 Ferroportin is therefore involved in the release of iron from macrophages as well as the transfer of absorbed iron to the systemic circulation. 19 The discovery of hepcidin, an acute-phase protein, furthered the understanding of the relationship between the inflammatory immune response and iron homeostasis. Both IL-6 and lipopolysaccharide induce hepcidin expression and production in the liver. Results from mouse models suggest that hepcidin may be centrally involved in the diversion of iron traffic by reducing duodenal iron absorption across the basolateral enterocyte membrane and blocking iron release from macrophages. 20 Consequently, there is limited iron available for utilization by erythroid progenitor cells, thus resulting in iron-restricted erythropoiesis as well as adversely impacting on the other key physiological roles of iron.
However, iron metabolism has yet to be fully investigated in patients with CHF and it remains unknown to what extent data from animal models can be extrapolated and applied to the clinical setting.
It is tempting to link iron deficiency in CHF with associated inflammation and to suggest that hepcidin may have a central role in the inhibition of iron absorption. 21 Recent studies, however, found rather low circulating levels of hepcidin in patients with CHF and reported no association between levels of proinflammatory cytokines (such as and overexpression of hepcidin. [22] [23] [24] Although markers of inflammation increased with worsening functional class, the inverse was true for hepcidin despite iron deficiency and iron-restricted erythropoiesis becoming increasingly common. Importantly, circulating levels of erythropoietin are often raised in heart failure, being higher in patients with worse functional class, and are correlated with adverse prognosis. 12 Erythropoietin is a powerful suppressor of hepcidin production, and this may to some extent explain the lower levels observed in those with worse symptoms. The underlying mechanism of iron deficiency in CHF remains incompletely understood and further work is needed to fully elucidate the precise pathophysiology, and this in turn may influence treatment strategies.
| DIAGNOSING IRON DEFICIENCY
As outlined above, iron exists in stored intracellular, circulating, and utilized forms, the latter predominantly within erythrocyte hemoglobin. The levels of all forms vary considerably and movement between them involves complex regulation in response to changing metabolic requirements and various pathophysiological processes. An optimal diagnostic test would simply and accurately measure all forms of iron as well as total body iron levels. Unfortunately, no such test exists. Table 1 
| PREVALENCE AND PROGNOSIS OF IRON DEFICIENCY IN HEART FAILURE
In recent years, there has been increased focus on the clinical importance of iron deficiency in patients with CHF. It is a frequent comorbidity with varying prevalence depending on study criteria and the definition of iron deficiency used. For example, in one study of 1506 stable CHF patients with both preserved and reduced left ventricular systolic function, 50% were reported to be iron-deficient. 25 When analyzed according to hemoglobin level, 46% of those without anemia and 61% of those with anemia were iron-deficient. 25 These results are similar to a recently published study of 4456 patients referred to a single outpatient heart failure service, which identified iron deficiency in 43%-68% of patients with anemia and 14%-35% of those with a normal hemoglobin depending on the definition of iron deficiency used. 26 There has only been one published study using the gold standard technique of bone marrow analysis, which examined 37 anemic patients with advanced severe heart failure and demonstrated iron deficiency in 73%. 27 Many studies have shown that iron deficiency is associated with exercise intolerance, reduced quality of life, and increased risk of hospitalization and mortality in CHF patients. [28] [29] [30] Although iron deficiency is frequently related to anemia, it is an independent predictor of symptom severity, exercise tolerance, and quality of life irrespective of hemoglobin status. 25, 29, 30 One study analyzed 3 years of follow-up as all-cause death and transplantation) was 54% in those with iron deficiency versus 67% in those without (Figure 1) . 29 in the placebo group (P = .23). Reports of thromboembolic adverse events were received from 153 patients (13.5%) and 114 patients (10.0%) from the darbepoetin alfa group and placebo group, respectively (P = .01). Darbepoetin alfa therefore did not reduce the rate of mortality or hospitalization among patients with CHF and associated anemia but conferred a significant increase in the risk of thromboembolic events. This study served to eliminate erythropoietin as a standard treatment for anemia in patients with CHF.
| IRON REPLACEMENT
Several small studies reported that intravenous (IV) iron was as- T A B L E 2 Summary of results of the meta-analysis of iron therapy in heart failure by Jankowska et al 43 
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Number randomized (n=) anemia. [37] [38] [39] Further data supporting benefit on exercise capacity have come from a recent study which demonstrated a significant improvement in peak oxygen uptake (VO 2 ) among symptomatic patients with stable heart failure treated with IV iron for 24 weeks as compared with placebo (P = .02). 40 In contrast, oral iron appears to have little effect on oxygen consumption or iron stores in patients with CHF. 41 This is likely due to the impaired duodenal absorption of iron in the context of the chronic inflammatory state described above.
To date, there have been two larger-scale clinical trials which reported the beneficial effects of IV iron therapy in CHF patients with iron deficiency. 21, 42 The FAIR-HF trial 42 was a randomized, double-blind study designed to determine whether the administration of IV iron (ferric carboxymaltose) conferred symptomatic benefit in iron-deficient CHF patients, either with or without anemia. In this study, 459 patients with CHF and NYHA functional class II or III were enrolled. Cutoff points for LVEF were ≤ 40%
and ≤ 45% for NYHA class II and III, respectively. Iron deficiency was defined as ferritin < 100 μg/L, or between 100 and 299 μg/L with transferrin saturation < 20%. The subjects were randomly assigned to receive either IV ferric carboxymaltose or saline (placebo). The primary endpoints were the self-reported patient global assessment and NYHA functional class, both recorded at week 24.
Among the patients who were given ferric carboxymaltose, 50%
reported being much or moderately improved, and 47% were in The beneficial effects of iron therapy were sustained throughout the period of study. Furthermore, although it was not powered to evaluate this, IV iron was associated with a reduction in the risk of hospitalization for worsening heart failure (HR 0.39, 95% CI 0.19-0.82, P = .009).
A recent meta-analysis by Jankowska et al 43 examined evidence from five randomized controlled trials, 21, 38, 39, 42, 44 involving a total of 851 patients-the majority being from FAIR-HF and CONFIRM-HF.
IV iron therapy improved symptoms, exercise capacity, quality of life, and clinical outcomes, regardless of concomitant anemia. Interestingly, the risk of cardiovascular hospitalization, heart failure hospitalization, cardiovascular death, and all-cause death appeared to be significantly reduced by IV iron therapy. Table 2 summarizes the key results from the meta-analysis.
| CURRENT GUIDELINES
In the latest clinical guideline published by the Scottish Intercollegiate
Guidelines Network (SIGN) on management of CHF, 45 patients with reduced ejection fraction, NYHA class III with an LVEF ≤ 45%, or NYHA class II, LVEF ≤ 40%, with a hemoglobin level of 9.5-13.5 g/dL and iron deficiency (defined as ferritin < 100 μg/L, or transferrin saturation < 20% with ferritin 100-300 μg/L) should be considered for IV iron therapy. IV ferric carboxymaltose is also shown to be cost-effective (£12,482 per QALY gained). 46 In addition, the SIGN guidelines state that erythropoietin is not recommended for CHF patients with reduced ejection fraction and anemia, mainly due to the absence of beneficial effects and the increased risk of thromboembolic adverse events. 45 The European Society of Cardiology (ESC) has also recently recommended that IV iron be considered in symptomatic patients with heart failure with reduced ejection fraction and iron deficiency (the same definitions applied as the SIGN guidelines)-Class IIa recommendation and Level A evidence. The primary purpose of this recommendation is for symptom alleviation and to improve exercise capacity and quality of life. Level B-R evidence). 48 However, the report also stated that a strong recommendation for IV iron replacement can only be made once results from a well-designed trial evaluating its effects on morbidity and mortality are available.
| FUTURE CHALLENGES
Major gaps of knowledge still exist. Although serum ferritin has been used in several of the studies, increasing amounts of data suggest that serum ferritin is not a robust indicator of iron deficiency. 26 Patients with CHF are less likely to have a low serum ferritin compared to patients without CHF. This may be attributed to the fact that ferritin is an acute-phase reactant which may be elevated in response to the underlying inflammatory process in CHF. [14] [15] [16] [17] [18] [19] [20] Consequently, iron deficiency may be missed if based on serum ferritin concentration as high levels of serum ferritin may reflect inflammation rather than iron repletion. Many patients with serum ferritin < 100 μg/L were also found not to have anemia, thus suggesting a poor correlation between serum ferritin levels and prevalence of anemia. 26 Therefore, the validity of serum ferritin as a tool used to define iron deficiency is questionable and further work is needed to evaluate other hematinic factors which may potentially be a better indicator of iron deficiency.
In addition, the longer-term impact of iron repletion on CHF hospitalization, overall hospitalization (used as an index of both morbidity and cost-effectiveness), cardiovascular mortality, and safety is still poorly understood. An ongoing UK-based study, IRONMAN, 49 is a prospective, randomized open-label, blinded endpoint trial aiming to evaluate these issues. The primary objective is to compare the additional effect of an IV iron regimen (iron isomaltoside-1000) when added to standard guideline-indicated therapy on cardiovascular mortality and recurrent hospitalizations due to heart failure in patients with CHF secondary to left ventricular systolic dysfunction and iron deficiency. A total of 1300 patients will be recruited with the study period planned to last for approximately 4.5 years. Further outcome studies are planned in Germany and the United States.
| CONCLUSION
Iron deficiency is very common in CHF and associated with an increased morbidity and mortality. IV iron therapy improves symptoms, exercise capacity, and quality of life, at least in the short-to-intermediate time.
However, there are still currently no standardized criteria used to define iron deficiency and the underlying mechanism of iron deficiency in CHF remains incompletely understood. Further work is required to improve the ability to identify iron deficiency in patients with CHF and evaluate the effect of iron repletion on hard endpoints including hospitalization and mortality.
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